Eribulin Mesylate Injection
Product Images NDC 10019-080

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 10019-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Eribulin Structural Formula (Image 01)

Chemical structure of Eribulin Mesylate, showing its detailed molecular configuration including rings, functional groups, and the mesylate component (CH3-SO3H).*

FDA Label Image

Eribulin Figure 1 (Eribulin Figure 1)

A survival curve chart comparing the proportion of patients alive over time (in months) between Eribulin Mesylate Injection (N=508) and a control group (N=254). The y-axis shows the proportion of patients alive from 0 to 1.0, and the x-axis shows time in months from 0 to 36. A table below shows the number of patients at risk for both groups at different time points.*

FDA Label Image

Eribulin Figure 2 (Image 03)

A Kaplan-Meier survival curve chart comparing survival probabilities over time (months) for Eribulin Mesylate Injection and Dacarbazine. The chart shows survival time on the x-axis and survival probability on the y-axis, including a legend for sample sizes at risk over time for both treatments.*

FDA Label Image

Eribulin Baxter Logo (Image 04)

FDA Label Image

Patient Information Table Of Symptoms (Image 05)

A partial drug facts or safety information panel listing symptoms such as fever, chills, cough, and burning or pain when urinating. The text appears as bulleted points describing possible side effects or reactions related to the medication.*

FDA Label Image

Patient Information Table Of Side Effects (1)

A text panel listing side effects associated with the drug, including low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation. The text is in black bullet points on a white background.*

FDA Label Image

Patient Information Table Of Side Effects (2)

Text listing several symptoms or side effects, including tiredness, nausea, hair loss (alopecia), constipation, stomach pain, and fever. The format appears as a bulleted list without additional context or headings.*

FDA Label Image

Eribulin Baxter Logo (Image 08)

FDA Label Image

Eriibulin Representative Container Label (NDC 10119-080-01)

Label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use, single dose vial. The label includes storage instructions and a caution that it is a cytotoxic agent. Distributed by Baxter Healthcare Corporation, Deerfield, IL.*

FDA Label Image

Eribulin Representative Carton Label (NDC 10119-080-01 -1 of 2)

Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use in a single-dose vial. The label indicates it is a cytotoxic agent, for prescription use only, supplied by Baxter Healthcare Company. Storage instructions specify keeping at 25°C with allowed excursions from 15° to 30°C and prohibiting freezing or refrigeration.*

FDA Label Image

Eribulin Representative Carton Label (NDC 10119-080-01 -2 of 2)

Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution in single-dose vial packaging. Label indicates intravenous use and cautions it as a cytotoxic agent. Distributed by Baxter Healthcare Corporation, product of Germany. Includes dual barcodes and standard regulatory markings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.